Clearmind Medicine Inc. (Nasdaq: CMND) has been granted U.S. Patent No. 12,350,242, titled "Binge Behavior Regulators," by the United States Patent and Trademark Office, according to a company statement.

The patent covers compositions and methods using a pharmaceutically acceptable salt of the company's molecule MEAI (5-methoxy-2-aminoindane) to regulate binge behaviors, including excessive drinking, eating, and gambling.

The grant brings Clearmind's total portfolio to 32 granted patents across 19 patent families. The company's lead candidate is CMND-100, a central nervous system therapeutic.

CEO Dr. Adi Zuloff-Shani said: "We believe that this milestone directly advances our clinical programs for binge-related disorders, such as alcohol use disorder, where patients urgently need more effective options."

Clearmind is a clinical-stage biotech company based in Vancouver, Canada, focused on developing non-hallucinogenic, neuroplastogen-derived therapeutics.